MAFG and cancer: Since TWEAK-mediated non-canonical NF-κB activation and the cooperativity of NF-κB/p52 with non-κB factors have been documented in cancer cells43,47,60, we hypothesised the possibility of p52 facilitating MAFG recruitment to enhancer sites following TWEAK treatment.